Invizyne Technologies (IZTC) Competitors $10.12 -0.53 (-4.98%) As of 04/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesOwnershipSEC FilingsTrendsBuy This Stock IZTC vs. MREO, SLDB, HRTX, ATXS, ALLO, AURA, RAPP, ARCT, CYRX, and GLUEShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Mereo BioPharma Group (MREO), Solid Biosciences (SLDB), Heron Therapeutics (HRTX), Astria Therapeutics (ATXS), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Rapport Therapeutics (RAPP), Arcturus Therapeutics (ARCT), Cryoport (CYRX), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry. Invizyne Technologies vs. Mereo BioPharma Group Solid Biosciences Heron Therapeutics Astria Therapeutics Allogene Therapeutics Aura Biosciences Rapport Therapeutics Arcturus Therapeutics Cryoport Monte Rosa Therapeutics Mereo BioPharma Group (NASDAQ:MREO) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has preferable earnings & valuation, MREO or IZTC? Invizyne Technologies has lower revenue, but higher earnings than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$1M342.87-$29.47M-$0.06-36.83Invizyne TechnologiesN/AN/AN/AN/AN/A Do institutionals & insiders hold more shares of MREO or IZTC? 62.8% of Mereo BioPharma Group shares are held by institutional investors. 4.1% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor MREO or IZTC? In the previous week, Mereo BioPharma Group had 12 more articles in the media than Invizyne Technologies. MarketBeat recorded 13 mentions for Mereo BioPharma Group and 1 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.67 beat Mereo BioPharma Group's score of 0.50 indicating that Invizyne Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mereo BioPharma Group 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Invizyne Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor MREO or IZTC? Mereo BioPharma Group received 52 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformMereo BioPharma GroupOutperform Votes5280.00% Underperform Votes1320.00% Invizyne TechnologiesN/AN/A Is MREO or IZTC more profitable? Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A N/A N/A Invizyne Technologies N/A N/A N/A Do analysts prefer MREO or IZTC? Mereo BioPharma Group currently has a consensus price target of $7.71, suggesting a potential upside of 249.06%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMereo BioPharma Group beats Invizyne Technologies on 9 of the 10 factors compared between the two stocks. Remove Ads Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.27M$2.98B$5.54B$7.50BDividend YieldN/A1.53%4.86%4.04%P/E RatioN/A30.4323.2418.07Price / SalesN/A383.25361.2586.83Price / CashN/A168.6838.1634.64Price / BookN/A3.646.493.99Net IncomeN/A-$72.06M$3.21B$247.18M7 Day Performance-0.10%-9.02%-4.91%-4.25%1 Month Performance-40.15%-16.50%-0.08%-6.87%1 Year PerformanceN/A-31.37%6.40%-3.73% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$10.12-5.0%N/AN/A$63.27MN/A0.00N/AMREOMereo BioPharma Group2.4078 of 5 stars$2.39-4.2%$7.83+228.4%-35.2%$370.02M$1M0.0040Analyst RevisionSLDBSolid Biosciences3.0437 of 5 stars$4.74-0.9%$15.67+230.6%-72.8%$366.54M$8.09M-1.56100Gap DownHRTXHeron Therapeutics3.3401 of 5 stars$2.39-1.9%$5.67+137.6%-16.7%$363.31M$144.29M-13.25300Gap DownATXSAstria Therapeutics1.471 of 5 stars$6.26-1.8%$26.60+325.3%-57.4%$355.25MN/A-3.0130Gap DownALLOAllogene Therapeutics2.3587 of 5 stars$1.62-3.9%$9.29+475.2%-66.3%$350.88M$22,000.00-1.04310Gap DownAURAAura Biosciences2.2698 of 5 stars$7.02+0.2%$23.00+227.8%-21.8%$350.56MN/A-4.0650Gap DownRAPPRapport Therapeutics1.6359 of 5 stars$9.55-6.6%$35.00+266.5%N/A$350.00MN/A-0.69N/AShort Interest ↑ARCTArcturus Therapeutics2.5943 of 5 stars$12.84-3.2%$59.20+361.1%-71.0%$349.58M$138.39M-5.81180Gap DownCYRXCryoport2.598 of 5 stars$6.85-3.5%$11.67+70.3%-70.3%$342.63M$228.39M-2.031,020Analyst ForecastGap DownGLUEMonte Rosa Therapeutics3.0064 of 5 stars$5.53-5.1%$15.50+180.3%-43.9%$340.98M$14.98M-3.0390Short Interest ↓Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Mereo BioPharma Group Alternatives Solid Biosciences Alternatives Heron Therapeutics Alternatives Astria Therapeutics Alternatives Allogene Therapeutics Alternatives Aura Biosciences Alternatives Rapport Therapeutics Alternatives Arcturus Therapeutics Alternatives Cryoport Alternatives Monte Rosa Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IZTC) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IZTC Stock Free IZTC Stock Alerts